Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
21 nov. 2024 08h19 HE
|
Biomerica, Inc.
New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
18 nov. 2024 08h00 HE
|
EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
18 nov. 2024 03h00 HE
|
EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
Taurex Launches Atmos: Redefining Secure and Transparent Prop Trading
15 nov. 2024 09h06 HE
|
Taurex
Taurex Launches Atmos: A New Standard in Secure and Transparent Prop Trading
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
12 nov. 2024 08h10 HE
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain
30 oct. 2024 08h19 HE
|
Biomerica, Inc.
Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from www.infoodsIBS.com without needing to visit a doctor’s officeWith a simple, at-home finger-prick...
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
22 oct. 2024 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
Oshi Health Raises $60M Series C to Strengthen Its Position as the Category Leader for Virtual Digestive Care
16 oct. 2024 08h00 HE
|
Oshi Health
Oshi Health Raises $60M Series C to Strengthen Its Position as the Category Leader for Virtual Digestive Care
Shaping the Future of Trading: Taurex Showcases Advanced Trading Solutions as Titanium Sponsor at Forex Expo Dubai 2024
14 oct. 2024 02h50 HE
|
Taurex
Shaping the Future of Trading:
Taurex Showcases Advanced Trading Solutions as Titanium Sponsor at Forex Expo Dubai 2024.
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
19 sept. 2024 09h00 HE
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...